Crohn's disease trials in Canada

In Canada 48 Also abroad 422

48 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Barrie, Calgary, Edmonton, Kentville, Lethbridge, Lévis, London, Mississauga, Montreal, New Westminster, Oakville, Québec, Toronto, Vancouver, Vaughan
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
No phaseTaking people
The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.
Where
Toronto
Age
18 years and over
People
40 worldwide
Run by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT06006039
Phase 2Taking people
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Where
Alberta, Chicoutimi, Halifax, Lethbridge, London, Montreal, Québec, Scarborough, Toronto, Vaughan
Age
18 years to 85 years
People
385 worldwide
Run by
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00
Phase 3Taking people
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Where
Edmonton, London, Montreal, Ottawa, Vancouver
Age
18 years to 70 years
People
290 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00
Phase 2Taking people
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Where
Greenfield Park, Lethbridge, London, Vaughan
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00
Phase 2Taking people
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Where
Greenfield Park, Lethbridge, London, Vaughan
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483099
Phase 3Taking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Halifax, London, Toronto
Age
2 years to 17 years
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Barrie, Edmonton, Kentville, London, Montreal, Oakville, Toronto, Vancouver
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
Phase 3Taking people
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Where
Edmonton, Hamilton, London, Montreal, Oshawa, Toronto, Vancouver
Age
18 years and over
People
530 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07499232
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Edmonton, Halifax, Kentville, London, Mississauga, Montreal, Toronto, Vancouver, Vaughan
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
Phase 2Taking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Calgary, Halifax, London, Montreal, New Westminster, Toronto
Age
18 years to 75 years
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
Phase 2Taking people
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Where
Québec
Age
18 years to 75 years
People
2,000 worldwide
Run by
AbbVie
See details and how to joinNCT07697456 · EU 2026-525959-86-00
Phase 4Taking people
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
Where
Brampton, Brantford, Calgary, Edmonton, Halifax, Hamilton, London, Mississauga, Montreal, Oakville, Oshawa, Ottawa, Sherbrooke, Thunder Bay, Toronto, Vancouver
Age
18 years and over
People
210
Run by
University of Calgary
See details and how to joinNCT05928039
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Barrie, Brampton, London, Montreal, North YORK
Age
16 years to 80 years
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
Phase 4Taking people
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
Where
Hamilton, London, Scarborough Village, Vancouver
Age
18 years and over
People
60 worldwide
Run by
Alimentiv Inc.
See details and how to joinNCT06997965
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Brampton, Edmonton, Greater Sudbury, Hamilton, London, Montreal, New Westminster, Oakville, Toronto
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Edmonton, Hamilton, London, New Westminster, Toronto
Age
16 years to 80 years
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Calgary, Edmonton, London, Vancouver
Age
2 years to 17 years
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Edmonton, Trois-Rivières, Vaughan
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
No phaseTaking people
Genome Analysis Across Populations in Inflammatory Bowel Disease
Where
Toronto
People
150
Run by
Mount Sinai Hospital, Canada
See details and how to joinNCT06042387
Phase 3Taking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
London, Toronto
Age
2 years to 19 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
Phase 3Taking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Halifax, London, Toronto, Vancouver
Age
2 years to 17 years
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
Phase 1Taking people
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Where
Toronto
Age
18 years and over
People
300 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT03816345
No phaseTaking people
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease
Where
Hamilton
Age
18 years to 70 years
People
15
Run by
McMaster University
See details and how to joinNCT06548399
No phaseTaking people
TIDHI Mental Health in IBD Patients Study
Where
North YORK
Age
18 years to 75 years
People
100
Run by
TIDHI Innovation Inc.
See details and how to joinNCT07013578